benzofuran-4-carbonyl chloride | 380899-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: benzofuran-4-carbonyl chloride
• 英文别名: 1-Benzofuran-4-carbonyl chloride
• CAS: 380899-56-9
• 化学式: C₉H₅ClO₂
• 分子量: 180.59
• InChiKey: LKRFEKDIARVXQR-UHFFFAOYSA-N

物化性质

• 沸点：
  260.8±13.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzofuran-4-carbonyl chloride 在 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 1.75h， 生成 4-苯并呋喃羧醛
  参考文献：
  名称：

  BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS

  摘要：

  公开号：

  EP1027043B1
• 作为产物：
  描述：

  methyl 3-(allyloxy)benzoate 在 氢氧化钾 、 氯化亚砜 、 二甲基硫 、 磷酸 、 臭氧 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 为溶剂， 反应 2.92h， 生成 benzofuran-4-carbonyl chloride
  参考文献：
  名称：

  Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics

  摘要：

  Aminoalkylindoles (AAIs) are a novel series of cannabinoid receptor ligands. In this report we disclose the structural features of AAIs which are important for binding to this receptor as measured by inhibition of binding of [H-3]Win 55212-2 (5). Functional activity in the mouse vas deferens is also noted and used to distinguish agonists from potential antagonists. The key structural features for potent cannabinoid activity in this series are a bicyclic (naphthyl) substituent at the 3-position, a small (II) substituent at the 2-position, and an aminoethyl (morpholinoethyl) substituent at the 1-position. A 6-bromo analog, Win 54461 (31), has been identified as a potential cannabinoid receptor antagonist. Modeling experiments were done to develop a pharmacophore and also to compare AAI structures with those of classical cannabinoids. The fact that the cannabinoid AAIs arose out of work on a series of cyclooxygenase inhibitors makes sense now that an endogenous cannabinoid ligand has been identified which is a derivative of arachidonic acid. Because of their unique structures and physical properties, AAIs provide useful tools to study the structure and function of the cannabinoid receptor(s).

  DOI：

  10.1021/jm00016a013

文献信息

• [EN] POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE<br/>[FR] FORMES POLYMORPHES DE (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMÉTHYL)-1-((4-(2-MÉTHYL-5-(4-FLUOROPHÉNYL)THIAZOLYL)CARBONYL)PIPÉRIDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009034133A1

  公开（公告）日：2009-03-19

  New crystalline forms of (S)-2-((4-benzofuranyl)carbonylamino methyl)-1-((4-(2-methyl-5-(4-fluorophenyl))thiazolyl)carbonyl)piperidine, methods for their preparation and use in medicine as orexin receptor antagonist.

  (S)-2-((4-苯并呋喃基)羰基氨甲基)-1-((4-(2-甲基-5-(4-氟苯基)噻唑基)羰基)哌啶的新结晶形式，其制备方法以及作为促觉醒素受体拮抗剂在医学上的用途。
• Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders
  作者：Romano Di Fabio、Annalisa Pellacani、Stefania Faedo、Adelheid Roth、Laura Piccoli、Philip Gerrard、Rod A. Porter、Christopher N. Johnson、Kevin Thewlis、Daniele Donati、Luigi Stasi、Simone Spada、Geoffrey Stemp、David Nash、Clive Branch、Leanda Kindon、Mario Massagrande、Alessandro Poffe、Simone Braggio、Elisabetta Chiarparin、Carla Marchioro、Emiliangelo Ratti、Mauro Corsi

  DOI：10.1016/j.bmcl.2011.06.086

  日期：2011.9

  clinical, suggests that the orexin system is profoundly implicated in sleep disorders. In particular, modulation of the orexin receptors activation by appropriate antagonists was proven to be an efficacious strategy for the treatment of insomnia in man. A novel, drug-like bis-amido piperidine derivative was identified as potent dual OX1 and OX2 receptor antagonists, highly effective in a pre-clinical

  下丘脑肽orexin-A和orexin-B是两种G蛋白偶联受体，即OX 1和OX 2受体的有效激动剂。这些受体在大鼠脑中分布广泛，尽管存在差异。特别是，OX 1受体在整个下丘脑中高度表达，而OX 2受体在整个下丘脑中都高度表达。受体主要位于腹后核。大量令人信服的证据（包括临床前和临床证据）表明，食欲素系统与睡眠障碍密切相关。特别地，通过适当的拮抗剂调节食欲素受体激活被证明是治疗人失眠的有效策略。一种新颖的，类似药物的双酰胺基哌啶衍生物被确定为有效的双重OX 1和OX 2受体拮抗剂，在临床前睡眠模型中非常有效。
• [EN] PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] PIPERIDINES UTILES EN TANT QU'ANTAGONISTES DU RECEPTEUR D'OREXINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001096302A1

  公开（公告）日：2001-12-20

  Compounds of formula (I) wherein Y represents a group (CH2)n, wherein n represents 0, 1 or 2; R1 is phenyl, naphthyl, a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; or a group NR3R4 wherein one of R?3 and R4¿ is hydrogen or optionally substituted (C¿1-4?)alkyl and the other is phenyl, naphthyl or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S, or R?3 and R4¿ together with the N atom to which they are attached form a 5 to 7-membered cyclic amine which has an optionally fused phenyl ring; any of which R1 groups may be optionally substituted; R2 represents phenyl or a 5- or 6-membered hereroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R5, and further optional substituents; or R2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R5 represents an optionally substituted (C¿1-4?)alkoxy, halo, optionally substituted (C1-6)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 3 heteroatoms selected from N, O and S; or pharmaceutically acceptable salts thereof.

  化合物的公式(I)，其中Y代表(CH2)n的基团，其中n代表0、1或2；R1是苯基、萘基、含有最多3个异原子（选自N、O和S）的单环或双环杂环基团；或者是NR3R4的基团，其中R?3和R4¿中的一个是氢或可选取代的(C¿1-4?)烷基，另一个是苯基、萘基或含有最多3个异原子（选自N、O和S）的单环或双环杂环基团，或者R?3和R4¿连同它们所连接的N原子形成一个5至7成员环状胺，该胺具有一个可选的融合苯环；任何R1基团都可以选择性地取代；R2代表苯基或含有最多3个异原子（选自N、O和S）的5-或6成员杂环基团，其中苯基或杂环基团被R5和其他可选取代基团取代；或者R2代表一个可选取代的含有最多3个异原子（选自N、O和S）的双环芳香基团或双环杂芳基团；R5代表一个可选取代的(C¿1-4?)烷氧基、卤素、可选取代的(C1-6)烷基、可选取代的苯基或含有最多3个异原子（选自N、O和S）的5-或6成员杂环环，或其药学上可接受的盐。
• Piperdines for use as orexin receptor antagonists
  申请人：——

  公开号：US20030186964A1

  公开（公告）日：2003-10-02

  Compounds of formula (I) wherein Y represents a group (CH 2 ) n , wherein n represents 0, 1 or 2; R 1 is phenyl, naphthyl, a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; or a group NR 3 R 4 wherein one of R 3 and R 4 is hydrogen or optionally substituted (C 1-4 )alkyl and the other is phenyl, naphthyl or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S, or R 3 and R 4 together with the N atom to which they are attached form a 5 to 7-membered cyclic amine which has an optionally fused phenyl ring; any of which R 1 groups may be optionally substituted; R 2 represents phenyl or a 5- or 6-membered hereroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R 5 , and further optional substituents; or R 2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R 5 represents an optionally substituted (C 1-4 )alkoxy, halo, optionally substituted (C 1-6 )alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 3 heteroatoms selected from N, O and S; or pharmaceutically acceptable salts thereof.

  式(I)的化合物，其中Y代表(CH2)n的基团，其中n代表0、1或2；R1是苯基、萘基、含有最多3个来自N、O和S的杂原子的单环或双环杂芳基基团；或者是NR3R4的基团，其中R3和R4中的一个是氢或者可选取代的(C1-4)烷基，另一个是苯基、萘基或含有最多3个来自N、O和S的杂原子的单环或双环杂芳基基团，或者R3和R4与它们所连接的N原子一起形成一个5-7环的环状胺，该环状胺具有可选的融合苯基环；其中任何一个R1基团都可以是可选的取代基；R2代表苯基或含有最多3个来自N、O和S的杂原子的5-或6-环杂芳基基团，其中苯基或杂芳基基团被R5和其他可选的取代基取代；或者R2代表一个可选的取代的双环芳香基或双环杂芳基基团，其中含有最多3个来自N、O和S的杂原子；R5代表一个可选的取代的(C1-4)烷氧基、卤素、可选的取代的(C1-6)烷基、可选的取代的苯基或含有最多3个来自N、O和S的杂原子的5-或6-环杂环基，或其药学上可接受的盐。
• PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1289955B1

  公开（公告）日：2005-04-13